TAKE A LOOK-Valeant cuts ties with beleaguered pharmacy

Fri Oct 30, 2015 3:59pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Adds story links)
    Oct 30 (Reuters) - Valeant Pharmaceuticals International Inc 
, seeking to allay investor concerns about its business practices, said
on Friday it is cutting ties with specialty pharmacy Philidor that is accused of
helping it inflate revenue.
    Following are key stories on Valeant:
    
  LATEST STORIES
> Valeant says Philidor shutting down as it cuts ties       
> Express Scripts reviews AbbVie, Teva ties to pharmacies   
> Ackman: Valeant's main problem is PR, not fraud           
> Citron tweets Valeant has chance of going to zero         
> CVS, Express Scripts drop Valeant's Philidor              
> Largest shareholder urges Valeant to pay down debt        
> FTC looking at Valeant's contact lens dealings -source    
> ValueAct rallies Valeant investors -source                
> Controversial pharma CEO Shkreli bails on Valeant         
> From pilot to profit-maker, pharmacy rose quickly         
> Valeant raises detailed defense but doubts remain         
    
  EARLIER STORIES  
> Valeant vows to refute 'phantom sales' allegations        
> Share price meltdown wipes $1.5 bln from CEO's wealth     
> Slump poses big threat to small hedge funds               
> Looming M&A hiatus deals blow to investment banks         
> Plunge spotlights cracks in specialty pharma's M&A facade 
> Shares plunge on short-seller scrutiny                    
> Specialty pharmacies in spotlight                         
> Class action lawsuit filed against Valeant                
> Valeant's unusual CEO comes under fire                    
> US CORP BOND WRAP-Healthcare rocked by more bad news      
> Falling secondary loan price pulls pharma down            
> Options volume explodes as traders dive for cover         
> Citron report on Valeant drags down biotechs              
> Meltdown costs investors billions; Ackman ups stake          
> CEO sees new drug pricing environment ahead               
> Clinton urges U.S. regulators to examine price hikes      
> Valeant subpoenaed by U.S. prosecutors                    
   
  OPINION
> Ackman's Valeant defense nervy but unpersuasive           
> Valeant's clarification efforts further tangle web        
> Valeant sets tone for accounting scrutiny                 

 (Compiled by Nick Zieminski)